



溫州康寧書院股份有限公司

Wenzhou Kangning Academy Co., Ltd.

(A joint stock limited liability company incorporated in the


2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Unaudited)
Revenue	465,150	378,910
Operating expenses	39,404	52,661
Operating income	(10,503)	(7,120)
Operating profit	28,901	45,541
Operating profit attributable to equity holders of the Company	36,410	52,064
Operating profit attributable to equity holders of the Company, after tax	(7,509)	(6,523)
As at	As at	
June 30,	June 30,	
2020	2019	
(RMB'000)	(RMB'000)	
(Unaudited)	(Unaudited)	
Operating assets	2,274,908	2,117,352
Operating liabilities	960,485	855,843
Operating assets less operating liabilities	1,314,423	1,261,509
Operating assets less operating liabilities, after tax	1,186,459	1,164,484
Operating assets less operating liabilities, after tax, attributable to equity holders of the Company	127,964	97,025

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review



4.1.1 Revenue and Cost of Revenue

Revenue is derived from the sale of products and services. The following table shows the revenue and cost of revenue for the six months ended June 30, 2020 and 2019.

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Revenue	438,886	360,210
Cost of revenue	19,116	15,281
Gross profit	7,148	3,419
Total revenue	465,150	378,910

... ..

(The music continues)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Audited)
In Patients		
Number of inpatients	6,853	5,593
Revenue from inpatients (RMB'000)	1,240,393	1,012,333
Revenue from inpatients (%)	83.1	84.9
Number of inpatient bed-days	1,030,392	859,061
Average inpatient spending per bed-day (RMB)	324,990	251,945
Number of inpatient visits	315	293
Revenue from inpatient visits (RMB'000)	53,841	50,926
Average inpatient spending per visit (RMB)	52	59
Total inpatient revenue (RMB'000)	378,831	302,871
Total average inpatient spending per bed-day (RMB)	368	353
Out Patients		
Number of outpatients	125,852	105,986
Revenue from outpatients (RMB'000)	12,761	11,635
Average outpatient spending per visit (RMB)	101	110
Number of outpatient visits	47,294	45,704
Revenue from outpatient visits (RMB'000)	376	431
Total outpatient revenue (RMB'000)	60,055	57,339
Total average outpatient spending per visit (RMB)	477	541
Total treatment and general healthcare services revenue (RMB'000)	337,751	263,580
Total pharmaceutical sales revenue (RMB'000)	101,135	96,630

378.8 2019, 25.1% 19.9% 4.2% 86.3% (30, 2019: 84.1%).

60.1 2019, 4.7% 18.7% 13.7% (30, 2019: 15.9%).

2019, 28.1% 77.0% 30, 2019: 73.2%); 4.7% 2019, 23.0% 30, 2019: 26.8%), 14.2% (30, 2019: 16.8%), 78.8% (30, 2019: 79.7%).

	For the six months ended June 30,	
	2020	2019
	(RMB'000)	('000)
	(Unaudited)	(Unaudited)
Cost of revenue of owned hospitals	112,156	101,813
Cost of revenue of hospitals under management	110,048	91,091
Cost of revenue of hospitals under joint management	15,297	14,119
Cost of revenue of hospitals under cooperation	37,019	30,236
Cost of revenue of hospitals under strategic cooperation	18,390	16,577
Cost of revenue of hospitals under other cooperation	11,647	7,807
Cost of revenue of hospitals under other cooperation	18,906	18,290
Cost of revenue of owned hospitals	323,463	279,933

323.5 15.6% 2019, () 28.1% 2019; () ; ()

34.7% (30, 2019: 36.4%). 34.0% (30, 2019: 32.5%).

4.1.2 Gross Profit and Gross Profit Margin

				128.3
		39.4%		
2019.				115.4
		43.8%		
2019.				

For the six months ended June 30,				
		2020	2019	
		(Unaudited)	()	
		29.7%	25.1%	
		14.9%	14.5%	
		26.3%	22.3%	
		47.1%	62.8%	
Consolidated gross profit margin		27.6%	24.3%	

		27.6% (	30, 2019: 24.3%),	
			4.6	
			2019,	


4.1.3 Tax and Surcharge

				2.0
		30, 2019:	0.8	()


4.1.4 Selling Expenses

				3.7
		30, 2019:	4.5	()
		0.8		2019.
		0.8%		(
		30, 2019: 1.2%).		

4.1.5 Administrative Expenses



4.1.9 Credit Impairment Losses



4.1.10 Non-Operating Income (Expenses) and Other Gains



4.1.11 Income Tax Expense

30, 2019:	7.1	10.5	(	47.5%
30, 2019,	26.7%	13.5%		
2019,				

4.2 Financial Position

4.2.1 Inventory

A 30, 2020,	33.9	(	
31, 2019:	23.6	(	
	31.3	(	
	2.6	(	
	2701,	2806,	2807
			2808

2701,	2806,	2807
2808		

A	
---	--

	75%
--	-----

(A,,.) (.)	19.3
--------------	------

(A,,.) (.)	325.73
--------------	--------

--	--

--	--

	30, 2017
--	----------

4.2.2 Accounts Receivables

At December 31, 2020, Accounts Receivable was 352.6 million (December 31, 2019: 310.5 million), an increase of 14.5% (December 31, 2019: 322.5 million). The increase was primarily due to an increase in the number of units sold in 2020 compared to 2019, and a decrease in the provision for doubtful accounts. The provision for doubtful accounts was 133 million (December 31, 2019: 146 million).

4.2.3 Other Receivables and Prepayments

At December 31, 2020, Other Receivables and Prepayments was 88.4 million (December 31, 2019: 68.7 million).

4.2.4 Investment Properties

At December 31, 2020, Investment Properties was 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4% (December 31, 2019: 302, 303, 304) (2/11/2020).

The decrease was primarily due to the sale of investment properties (December 31, 2019: 302, 303, 304).

At December 31, 2020, Investment Properties was 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4% (December 31, 2019: 302, 303, 304).

The decrease was primarily due to the sale of investment properties, 75%.

At December 31, 2020, Investment Properties was 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4% (December 31, 2019: 302, 303, 304).

The decrease was primarily due to the sale of investment properties, 75%.

At December 31, 2020, Investment Properties was 107.1 million (December 31, 2019: 110.9 million), a decrease of 3.4% (December 31, 2019: 302, 303, 304).

29, 2043, $462.9(24)$ (2/11/15)

4.2.8 Contract Liability

As at June 30, 2020, the Company's contract liability was RMB10.8 million (June 30, 2019: RMB8.6 million).

4.2.9 Other Payables

As at June 30, 2020, the Company's other payables were RMB93.5 million (June 30, 2019: RMB133.3 million).

4.3 Liquidity and Capital Resources

The following table summarizes the Company's cash flows for the six months ended June 30, 2020 and 2019:

	For the six months ended June 30,	
	2020 (RMB'000) (Unaudited)	2019 (RMB'000) (Audited)
Cash generated from operating activities	17,799	4,157
Cash used in investing activities	(76,436)	(75,880)
Cash generated from financing activities	94,945	(25,941)
Net change in cash and cash equivalents	<u>36,424</u>	<u>(98,423)</u>


4.3.1 Net Cash Generated from Operating Activities

	2020	2019
Net cash generated from operating activities	17.8	28.9
Net cash used in investing activities	16.1	60.0
Net cash generated from financing activities	90.9	14.5
Net change in cash and cash equivalents		


4.3.2 Net Cash Used in Investing Activities

	2020	2019
Net cash used in investing activities	67.1	76.4
Net cash generated from operating activities		
Net cash generated from financing activities		
Net change in cash and cash equivalents		

4.3.3 Net Cash Generated from Financing Activities




4.3.4 Significant Investment, Acquisition and Disposal



4.4 Indebtedness

4.4.1 Bank Borrowings



4.4.2 Contingent Liability



4.4.3 Asset Pledge



4.4.4 Lease Liabilities



4.4.5 Financial Instruments



4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's exposure to fluctuations in exchange rates arises from its operations in foreign currencies. The Group's functional currency is the Hong Kong dollar. The Group's exposure to fluctuations in exchange rates arises from its operations in foreign currencies. The Group's functional currency is the Hong Kong dollar. The Group's exposure to fluctuations in exchange rates arises from its operations in foreign currencies. The Group's functional currency is the Hong Kong dollar.

4.4.7 Gearing Ratio

At 30, 2020, the Group's gearing ratio (total debt divided by total equity) was 42.2% (31, 2019: 40.4%).

4.4.8 Employees and Remuneration Policy

At 30, 2020, the Group had 3,136 employees (31, 2019: 2,845). The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees.

The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees.

At 30, 2020, the Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is designed to attract, retain and motivate employees.

15,888,990. ☒ 899,700
 \$15,888,990. ☒ ()
☒ :

13, 2020.

30, 2020

7 REVIEW OF INTERIM RESULTS

30, 2020,

Let $A_1, \dots, A_n$ be n $\mathbb{A}^1$ -homotopy invariant presheaves of $\mathbb{A}^1$ -local Nisnevich sheaves on $\mathcal{S}_h$. Then $A_1 \otimes \dots \otimes A_n$ is $\mathbb{A}^1$ -homotopy invariant and $\mathbb{A}^1$ -local Nisnevich sheaf on $\mathcal{S}_h$. Moreover, $A_1 \otimes \dots \otimes A_n$ is $\mathbb{A}^1$ -homotopy invariant presheaf of $\mathbb{A}^1$ -local Nisnevich sheaves on $\mathcal{S}_h$.

8 INTERIM DIVIDEND

30, 2020 (2020年10月30日); 30, 2019: (2019年10月30日)).

9 COMPLIANCE WITH CG CODE


10 ACCOUNTING STANDARDS

In 2017, A total of 622 companies were registered under the Companies Ordinance).

11 FINANCIAL REPORT

11.1 Accounting Policies

2006.  (the “Ministry of Finance”) dated 15,

32 

2019. 2019.

2016.

11.2 Interim Financial Statement

As at June 30, 2020, the Company's interim consolidated financial statements were prepared on a going concern basis. The Company's interim consolidated financial statements were prepared on a going concern basis.

11.2.1 Interim Consolidated Income Statement

(Amounts in thousands of US dollars)

	For the six months ended	
	June 30,	2019
	2020	2019
	(Unaudited)	(Unaudited)
1. Revenue	465,150,452	378,910,291
Cost of sales	(336,864,754)	(286,882,183)
Gross profit	(1,999,246)	(831,972)
Selling, general and administrative expenses	(3,697,157)	(4,476,806)
Research and development expenses	(54,639,015)	(52,890,346)
Depreciation and amortization	(2,637,407)	(2,304,024)
Impairment losses	(11,846,196)	(10,198,874)
Other income	(14,086,629)	(11,068,131)
Income before income taxes	2,454,371	1,925,426
Income taxes	5,443,616	6,567,461
Net income	(923,557)	23,549,073
Other comprehensive income	(1,019,927)	(2,525,317)
Comprehensive income	(16,112,650)	(10,730,916)
Net income attributable to common shareholders	-	(18,587)68.6%

11.2.2 Interim Consolidated Statement of Financial Position

(Amounts in thousands of US dollars)

ASSETS	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Current assets		
Accounts receivable	216,156,858	176,030,550
Prepaid expenses and other assets	–	30,000,000
Accounts payable	352,645,140	310,520,612
Accrued expenses and other liabilities	76,843,282	63,317,366
Accrued interest	11,516,259	5,366,020
Income taxes payable	33,858,107	23,568,236
Other assets	–	12,688,704
Total current assets	691,019,646	621,491,488
Non-current assets		
Property, plant and equipment	51,281,869	51,281,869
Goodwill	94,068,266	89,943,193
Intangible assets	(94,068,266)	156,358,193
Other non-current assets	156,358,193	25,459,000

LIABILITIES AND SHAREHOLDERS' EQUITY	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Current liabilities		
Accounts payable	332,500,000	250,000,000
Accounts receivable	576,686	—
Accounts payable and accrued liabilities	63,565,539	75,554,960
Accounts receivable	10,772,528	8,562,126
Accounts payable and accrued liabilities	23,923,352	36,063,277
Accounts payable and accrued liabilities	44,736,621	33,430,060
Accounts payable and accrued liabilities	93,516,092	133,348,712
Accounts payable and accrued liabilities	66,053,557	79,741,922
Total current liabilities	635,644,375	616,701,057
Non-current liabilities		
Accounts payable	100,500,000	20,000,000
Accounts payable	186,013,332	183,808,151
Accounts payable	580,000	2,260,000
Accounts payable	2,000,000	2,000,000
Accounts payable	9,797,371	9,949,267
Accounts payable	25,949,596	21,124,118
Total non-current liabilities	324,840,299	239,141,536
Total liabilities	960,484,674	855,842,593
Shareholders' equity		
Accounts payable	75,500,000	75,500,000
Accounts payable	826,376,743	824,715,445
Accounts payable	(37,817,508)	(21,721,144)
Accounts payable	33,189,321	33,189,321
Accounts payable	289,210,662	252,800,715
Total equity attributable to shareholders of the Parent company	1,186,459,218	1,164,484,337
Accounts payable	127,964,021	97,024,925
Total shareholders' equity	1,314,423,239	1,261,509,262
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	2,274,907,913	2,117,351,855

11.2.3 Interim Consolidated Statements of Cash Flow

(All figures are in thousands of US dollars)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Unaudited)
1. Cash flows from operating activities		
Net income	411,405,749	337,771,543
Adjustments to reconcile net income to net cash flows from operating activities:	8,311,056	7,188,089
Depreciation and amortization		
Provision for doubtful accounts		
Gain on sale of property, plant and equipment		
Loss on sale of investments		
Change in accounts receivable		
Change in accounts payable		
Change in other assets and liabilities		
Sub-total of cash inflows	419,716,805	344,959,632
Payments for:		
Property, plant and equipment	(174,912,876)	(153,687,796)
Intangible assets	(162,022,960)	(137,201,128)
Acquisition of subsidiaries, net of cash acquired	(14,474,391)	(20,832,826)
Other cash outflows	(50,507,831)	(29,080,692)
Sub-total of cash outflows	(401,918,058)	(340,802,442)
Net cash flows from operating activities	17,798,747	4,157,190
2. Cash flows from investing activities		
Proceeds from the sale of property, plant and equipment	30,010,000	447,095
Proceeds from the sale of intangible assets	96,370	-
Proceeds from the sale of investments	3,870,905	-
Proceeds from the sale of other assets	-	1,833,758
Payments for the acquisition of property, plant and equipment	-	2,555,426
Sub-total of cash inflows	33,977,275	4,836,279
Payments for:		
Acquisition of property, plant and equipment	(67,075,009)	(63,099,075)
Acquisition of intangible assets	(15,145,000)	(13,020,000)
Acquisition of investments	(25,593,510)	(1,246,349)
Acquisition of other assets	(2,600,000)	(3,351,048)
Sub-total of cash outflows	(110,413,519)	(80,716,472)
Net cash flows used in investing activities	(76,436,244)	(75,880,193)

	For the six months ended	
	June 30,	
	2020	2019
	(Unaudited)	(Audited)
3. Cash flows from financing activities		
Proceeds from the issuance of long-term debt	23,361,500	4,245,000
Proceeds from the issuance of short-term debt	21,771,500	4,245,000
Proceeds from the issuance of equity	367,285,789	170,000,000
Proceeds from the issuance of capital	—	—
Sub-total of cash inflows	390,647,289	174,245,000
Payments for the redemption of long-term debt	(201,900,000)	(146,000,000)
Payments for the redemption of short-term debt	(8,241,036)	(6,647,896)
Payments for the redemption of equity	(85,561,157)	(47,538,263)
Sub-total of cash outflows	(295,702,193)	(200,186,159)
Net cash flows generated from/(used in) financing activities	94,945,096	(25,941,159)
4. Effect of foreign exchange rate changes on cash and cash equivalents	116,743	(758,597)
5. Net increase/(decrease) in cash and cash equivalents	36,424,342	(98,422,759)

11.2.4 Interim Consolidated Statement of Changes in Shareholders' Equity

(Amounts in thousands of U.S. dollars)

	Equity attributable to shareholders of the parent company						
	Share capital	Capital surplus	Less: Treasury stock	Surplus reserve	Retained earnings	Non-controlling interests	Total shareholders' equity
Balance at January 1, 2020	<u>75,500,000</u>	<u>824,715,445</u>	<u>(21,721,144)</u>	<u>33,189,321</u>	<u>252,800,715</u>	<u>97,024,925</u>	<u>1,261,509,262</u>
Net income	-	-	-	-	36,409,947	(7,508,712)	28,901,235
Dividends paid	-	-	-	-	-	21,771,500	21,771,500
Share-based compensation	-	3,914,851	(1,590,000)	-	-	-	2,324,851
Share repurchases	-	(2,253,553)	-	-	-	(1,709,223)	(3,962,776)
Other	-	-	(14,506,364)	-	-	-	(14,506,364)

11.3 Notes to the Interim Financial Statement Prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts Receivable

(Amount in thousands of RMB)

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Accounts receivable	6,750,000	8,250,000
Allowance for doubtful accounts	384,779,056	330,174,215
Accounts receivable, net	391,529,056	338,424,215
Less: Accounts receivable, net of allowance for doubtful accounts	(38,883,916)	(27,903,603)
	352,645,140	310,520,612

The accounts receivable as of June 30, 2020 and June 30, 2019 are classified as current assets.

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Accounts receivable	307,256,118	266,932,953
1. 2 years	54,328,309	57,988,407
2. 3 years	24,130,088	13,089,001
3. 4 years	5,814,541	413,854
	391,529,056	338,424,215

Accounts receivable are classified as current assets.

11.3.2 Accounts Payable

(All figures are in thousands of dollars)

The following table shows the components of accounts payable as of June 30, 2020 and June 30, 2019.

	June 30, 2020 (Unaudited)	June 30, 2019 (Audited)
Accounts payable	54,973,453	65,881,555
Accounts receivable	5,224,098	7,479,995
Accounts payable	2,277,029	1,381,101
Accounts payable	578,371	506,880
Accounts payable	276,874	94,816
Accounts payable	235,714	210,613
	<u>63,565,539</u>	<u>75,554,960</u>

11.3.3 Revenue and Cost of Sales

(All figures are in thousands of dollars)

	For the six months ended June 30,	
	2020 (Unaudited)	2019 (Audited)
Revenue	438,885,748	360,209,402
Cost of sales	26,264,704	18,700,889
	<u>465,150,452</u>	<u>378,910,291</u>
Revenue	323,463,045	279,933,288
Cost of sales	13,401,709	6,948,895
	<u>336,864,754</u>	<u>286,882,183</u>

Revenue and cost of sales from main operations

(Amount in thousands of Philippine pesos)

	For the six months ended June 30, 2020	
	(Unaudited) Revenue from main operations	(Unaudited) Cost of sales from main operations
Revenue from sales of finished goods	101,134,489	86,044,257
Revenue from sales of raw materials	337,751,259	237,418,788
	<u>438,885,748</u>	<u>323,463,045</u>
	For the six months ended June 30, 2019	
	(Unaudited) Revenue from main operations	(Unaudited) Cost of sales from main operations
Revenue from sales of finished goods	96,629,883	82,628,810
Revenue from sales of raw materials	263,579,519	197,304,478
	<u>360,209,402</u>	<u>279,933,288</u>

11.3.4 Earnings Per Share

(A) 11/1/2018 to 6/30/2020

() 11/1/2018 to 6/30/2020

	For the six months ended June 30,	
	2020 (Unaudited)	2019 ()
Net income	36,409,947	52,064,124
Weighted average number of shares outstanding	72,769,749	73,040,000
Earnings per share	0.50	0.71

() 11/1/2018 to 6/30/2020

13, 2018, 2,460,000

A 7, 2,460,000

30, 2020.

30, 2020, 899,700

() 11/1/2018 to 6/30/2020

30, 2020, 36,409,947.

73,034,363. 0.50.

30, 2019, 52,064,124.

73,915,743. 0.70.

11.3.5 Income Tax Expense

(Amounts in thousands of dollars)

	For the six months ended June 30,	
	2020 (Unaudited)	2019
Income tax expense	23,778,834	14,824,769
Deferred income tax expense	(13,276,086)	(7,704,851)
	<u>10,502,748</u>	<u>7,119,918</u>
Income tax expense	39,403,983	52,661,149
Income tax expense	9,850,996	13,165,287
Income tax expense	579,650	1,158,271
Income tax expense	121,674	119,184
Income tax expense	(490,212)	(431,227)
Income tax expense	—	(318,561)
Income tax expense	440,640	51,944
Income tax expense	—	(6,624,980)
	<u>10,502,748</u>	<u>7,119,918</u>

11.3.6 Dividends

12 DEFINITIONS

A	(北京怡寧醫院有限公司), 17, 2015,
	(蒼南康寧醫院有限公司), 15, 2012,
	(長春康林心理醫院有限公司), 16, 2016,
	(: 2120)
A	14
()	()
()	() 1.00
	(溫州怡寧老年醫院有限公司), 2, 2015,
()	()

\$—, —	
	A
	(淮南康寧醫院有限公司),
	22, 2017,
	(廊坊怡寧醫院有限公司,
	(廊坊市怡寧醫院管理有限公司)),
	2, 2015,
	A 2, 2020
	(台州市路橋慈寧醫院有限公司,
	(台州市路橋怡寧醫院有限公司)),
	12, 2016,
	A
	(青田康寧醫院有限公司),
	A, 1, 2011,
	(衢州怡寧醫院有限公司),
	20, 2015,
	30, 2020

, %—

7

[illegible]